Min M Lu

US Patent:

6506554, Jan 14, 2003

Filed:

Jan 18, 2000

Appl. No.:

09/484925

Inventors:

David C. Chan - Brookline MA
Deborah Fass - Cambridge MA
Min Lu - New York NY
James M. Berger - Cambridge MA
Peter S. Kim - Lexington MA

Assignee:

Whitehead Institute for Biomedical Research - Cambridge MA

International Classification:

C12Q 170

US Classification:

435 5, 435236, 530350, 436501, 436 86

Abstract:

Described are the crystal structure of the -helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.

US Patent:

7402396, Jul 22, 2008

Filed:

Oct 7, 2003

Appl. No.:

10/680853

Inventors:

David C. Chan - Brookline MA, US
Deborah Fass - Cambridge MA, US
Min Lu - New York NY, US
James M. Berger - Cambridge MA, US
Peter S. Kim - Lexington MA, US

Assignee:

Whitehead Institute for Biomedical Research - Cambridge MA

International Classification:

G01N 33/53

US Classification:

435 71, 435 5

Abstract:

Described are the crystal structure of the α-helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.

US Patent:

20030099935, May 29, 2003

Filed:

Jul 18, 2002

Appl. No.:

10/200007

Inventors:

David Chan - Brookline MA, US
Deborah Fass - Cambridge MA, US
Min Lu - New York NY, US
James Berger - Cambridge MA, US
Peter Kim - Lexington MA, US

Assignee:

Whitehead Institute for Biomedical Research - Cambridge MA

International Classification:

C12Q001/70

US Classification:

435/005000

Abstract:

Described are the crystal structure of the -helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.

US Patent:

61500887, Nov 21, 2000

Filed:

Apr 17, 1998

Appl. No.:

9/062241

Inventors:

David C. Chan - Brookline MA
Deborah Fass - Cambridge MA
Min Lu - New York NY
James M. Berger - Cambridge MA
Peter S. Kim - Lexington MA

Assignee:

Whitehead Institute for Biomedical Research - Cambridge MA

International Classification:

C12Q 170
C12P 2106
A61K 3800
C07K 500

US Classification:

435 5

Abstract:

Described are the crystal structure of the. alpha. -helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.

US Patent:

20220259188, Aug 18, 2022

Filed:

Jun 1, 2020

Appl. No.:

17/614732

Inventors:

Hua ZHOU - Boston MA, US
Michael J. ARDOLINO - Boston MA, US
Yi-Heng CHEN - Kenilworth NJ, US
Peter H. FULLER - Boston MA, US
Anmol GULATI - Boston MA, US
Rebecca Elizabeth JOHNSON - Boston MA, US
William P. KAPLAN - Boston MA, US
Solomon D. KATTAR - Boston MA, US
Mitchell H. KEYLOR - Boston MA, US
Derun LI - Boston MA, US
Kaitlyn Marie LOGAN - Boston MA, US
Min LU - Boston MA, US
Gregori J. MORRIELLO - Kenilworth NJ, US
Santhosh F. NEELAMKAVIL - Edison NJ, US
Barbara PIO - Kenilworth NJ, US
Nunzio SCIAMMETTA - Boston MA, US
Vladimir SIMOV - Boston MA, US
Jing SU - Kenilworth NJ, US
Luis TORRES - Norwood MA, US
Xin YAN - Boston MA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 405/14
C07D 487/08
C07D 409/14
C07D 403/04
C07D 403/14
C07D 498/04
C07D 498/08
C07D 487/10
C07D 401/14
C07D 471/10
C07D 491/107
C07D 471/04
C07D 487/04
A61P 25/16

Abstract:

The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

US Patent:

20210403469, Dec 30, 2021

Filed:

Nov 1, 2019

Appl. No.:

17/289062

Inventors:

- Rahway NJ, US
David Jonathan Bennett - Winchester MA, US
Indu Bharathan - Somerville MA, US
Liangqin Guo - Monroe Township NJ, US
Brett A. Hopkins - Brownsburg IN, US
Xianhai Huang - Warren NJ, US
Derun Li - West Roxbury MA, US
Min Lu - Brookline MA, US
Alexander Pasternak - Jamaica Plain MA, US
David L. Sloman - Newton MA, US
Hongjun Zhang - Boston MA, US
Hua Zhou - Acton MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 471/04
C07D 401/04
C07D 215/14
C07D 209/94
C07D 403/04

Abstract:

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

US Patent:

20210206796, Jul 8, 2021

Filed:

Dec 17, 2018

Appl. No.:

16/771814

Inventors:

Brian M. ANDRESEN - Boston MA, US
Frank BENNETT - Rahway NJ, US
Wonsuk CHANG - Kenilworth NJ, US
Matthew Lloyd CHILDERS - Boston MA, US
Jared N. CUMMING - Boston MA, US
Jongwon LIM - Boston MA, US
Min LU - Boston MA, US
Benjamin Wesley TROTTER - Boston MA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07H 21/00
A61P 37/04

Abstract:

A class of polycyclic compounds of general formula (I), wherein Base, Base, Y, Z, X, X, X, X, X, X, X, X, R, R, R, R, R, R, R, R, R, R, R, R, R, Rand Rare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

US Patent:

20210163505, Jun 3, 2021

Filed:

Jun 14, 2019

Appl. No.:

16/973623

Inventors:

- Rahway NJ, US
Jared N. Cumming - Winchester MA, US
Christian Fischer - Natick MA, US
Symon Gathiaka - Waltham MA, US
Charles A. Lesburg - Newton MA, US
Derun Li - West Roxbury MA, US
Min Lu - Brookline MA, US
Matthew J. Mitcheltree - Boston MA, US
Anandan Palani - Needham MA, US
Rachel L. Palte - Melrose MA, US
David L. Sloman - Brookline MA, US
Hongjun Zhang - Boston MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07F 5/02
C07K 16/28

Abstract:

Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.